Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 3, Two-Stage, Randomized, Multicenter, Open-label Study Comparing Iberdomide, Daratumumab and Dexamethasone (IberDd) versus Daratumumab, Bortezomib, and Dexamethasone (DVd) in Subjects with Relapsed or Refractory Multiple Myeloma (RRMM) (EXCALIBER-RRMM)

Next Previous
Trial Profile

A Phase 3, Two-Stage, Randomized, Multicenter, Open-label Study Comparing Iberdomide, Daratumumab and Dexamethasone (IberDd) versus Daratumumab, Bortezomib, and Dexamethasone (DVd) in Subjects with Relapsed or Refractory Multiple Myeloma (RRMM) (EXCALIBER-RRMM)

Status: Active, no longer recruiting
Phase of Trial: Phase III

Latest Information Update: 19 Oct 2026

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Bortezomib (Primary) ; Daratumumab (Primary) ; Daratumumab/hyaluronidase (Primary) ; Dexamethasone (Primary) ; Iberdomide (Primary)
  • Indications Multiple myeloma
  • Focus Registrational; Therapeutic Use
  • Acronyms EXCALIBER-RRMM
  • Sponsors Bristol-Myers Squibb; Celgene Corporation

Most Recent Events

  • 08 Oct 2026 According to Bristol Myers Squibb media release, data will be presented at the 68th Annual Meeting of the American Society of Hematology in New Orleans, L.A.
  • 08 Oct 2026 According to Bristol Myers Squibb media release, minimal residual disease (MRD)-negative complete response data were presented at the International Myeloma Society 23rd annual meeting and simultaneously published in Lancet Oncology.
  • 08 Oct 2026 Primary endpoint (Progression-free Survival (PFS)) has been met, according to Bristol Myers Squibb media release.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top